241 related articles for article (PubMed ID: 34571050)
1. Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial.
Patel VC; Lee S; McPhail MJW; Da Silva K; Guilly S; Zamalloa A; Witherden E; Støy S; Manakkat Vijay GK; Pons N; Galleron N; Huang X; Gencer S; Coen M; Tranah TH; Wendon JA; Bruce KD; Le Chatelier E; Ehrlich SD; Edwards LA; Shoaie S; Shawcross DL
J Hepatol; 2022 Feb; 76(2):332-342. PubMed ID: 34571050
[TBL] [Abstract][Full Text] [Related]
2. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
[TBL] [Abstract][Full Text] [Related]
3. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
4. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
5. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy.
Bajaj JS; Sikaroodi M; Shamsaddini A; Henseler Z; Santiago-Rodriguez T; Acharya C; Fagan A; Hylemon PB; Fuchs M; Gavis E; Ward T; Knights D; Gillevet PM
Gut; 2021 Jun; 70(6):1162-1173. PubMed ID: 32998876
[TBL] [Abstract][Full Text] [Related]
6. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
Saboo K; Shamsaddini A; Iyer MV; Hu C; Fagan A; Gavis EA; White MB; Fuchs M; Heuman DM; Sikaroodi M; Iyer RK; Gillevet PM; Bajaj JS
J Hepatol; 2021 Jan; 74(1):80-88. PubMed ID: 32679299
[TBL] [Abstract][Full Text] [Related]
7. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C; Thabut D; Jezequel C; Archambeaud I; D'Alteroche L; Dharancy S; Borentain P; Oberti F; Plessier A; De Ledinghen V; Ganne-Carrié N; Carbonell N; Rousseau V; Sommet A; Péron JM; Vinel JP
Ann Intern Med; 2021 May; 174(5):633-640. PubMed ID: 33524293
[TBL] [Abstract][Full Text] [Related]
8. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Flamm SL
Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
[TBL] [Abstract][Full Text] [Related]
9. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
[TBL] [Abstract][Full Text] [Related]
11. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
Kulkarni AV; Avadhanam M; Karandikar P; Rakam K; Gupta A; Simhadri V; Premkumar M; Zuberi AA; Gujjarlapudi D; Narendran R; Shaik S; Sharma M; Iyengar S; Alla M; Venishetty S; Reddy DN; Rao PN
Am J Gastroenterol; 2024 May; 119(5):864-874. PubMed ID: 37942950
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
13. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
14. The Use of Rifaximin in Patients With Cirrhosis.
Caraceni P; Vargas V; Solà E; Alessandria C; de Wit K; Trebicka J; Angeli P; Mookerjee RP; Durand F; Pose E; Krag A; Bajaj JS; Beuers U; Ginès P;
Hepatology; 2021 Sep; 74(3):1660-1673. PubMed ID: 33421158
[TBL] [Abstract][Full Text] [Related]
15. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome.
Yu X; Jin Y; Zhou W; Xiao T; Wu Z; Su J; Gao H; Shen P; Zheng B; Luo Q; Li L; Xiao Y
Front Cell Infect Microbiol; 2021; 11():761192. PubMed ID: 35118004
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
[TBL] [Abstract][Full Text] [Related]
17. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial.
Kimer N; Gudmann NS; Pedersen JS; Møller S; Nielsen MJ; Leeming DJ; Karsdal MA; Møller HJ; Bendtsen F; Grønbæk H
PLoS One; 2018; 13(9):e0203200. PubMed ID: 30183743
[TBL] [Abstract][Full Text] [Related]
18. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
Bajaj JS
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
[TBL] [Abstract][Full Text] [Related]
19. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.
Bajaj JS; Heuman DM; Sanyal AJ; Hylemon PB; Sterling RK; Stravitz RT; Fuchs M; Ridlon JM; Daita K; Monteith P; Noble NA; White MB; Fisher A; Sikaroodi M; Rangwala H; Gillevet PM
PLoS One; 2013; 8(4):e60042. PubMed ID: 23565181
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin for prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Zacharias HD; Kamel F; Tan J; Kimer N; Gluud LL; Morgan MY
Cochrane Database Syst Rev; 2023 Jul; 7(7):CD011585. PubMed ID: 37467180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
